Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?
Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?
复制标题
DOI：
10.1186/s13550-018-0447-8
复制
发表时间：
2018-10-05
期刊：
影响因子：
3.2
通讯作者：
Shiga T
中科院分区：
文献类型：
--
作者：
Furuya S;Manabe O;Ohira H;Hirata K;Aikawa T;Naya M;Tsujino I;Koyanagawa K;Anzai T;Oyama-Manabe N;Shiga T
心脏结节病（CS）是一种罕见但可能危及生命的疾病，可引起传导障碍，收缩功能障碍，最值得注意的是，心脏性猝死。18F-脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）不仅对CS的诊断有重要作用，而且对抗炎治疗的疗效评价也有重要意义。FDG PET测量的参数的基于体积的分析，即所谓的心脏代谢体积（CMV），已成为一种新的评估工具。CMV测量为由参考组织（例如肝脏和血池摄取）确定的边界内的体积。然而，口服类固醇治疗可能会导致肝脏和血池吸收的变化。在这里，我们试图评估类固醇对肝脏和血池吸收的影响。共38例CS患者在类固醇治疗前和治疗期间接受了FDG PET/CT。在肝右叶和降主动脉（DA）中放置感兴趣动脉（VOI）。比较激素治疗前和治疗期间肝脏和DA的最大标准化摄取值（SUVmax）、SUVmean和SUVpeak。类固醇治疗期间肝脏的SUV最大值、SUV平均值和SUV峰值较治疗前的时间点显著增加（SUV最大值3.5 ± 0.4 vs. 3.8 ± 0.6，p = 0.014; SUV平均值2.7 ± 0.3 vs. 3.0 ± 0.5，p = 0.0065; SUV峰值3.0 ± 0.4 vs. 3.4 ± 0.6，p = 0.006）。然而，DA中的SUV最大值、SUV平均值和SUV峰值没有显著变化（SUV最大值2.2 ± 0.3 vs. 2.2 ± 0.4，p = 0.46; SUV平均值1.9 ± 0.3 vs. 2.0 ± 0.4，p = 0.56; SUV峰值2.0 ± 0.3 vs. 2.0 ± 0.3，p = 0.70）。我们测量了类固醇治疗前和治疗期间肝脏和血池的FDG摄取。类固醇治疗增加肝脏摄取，但不是血池摄取。我们的研究结果表明，DA摄取是一个更合适的阈值，比肝脏摄取，以评估治疗效果的心脏FDG PET的体积为基础的分析。
Cardiac sarcoidosis (CS) is a rare but potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and, most notably, sudden cardiac death. 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays important roles not only in diagnosing CS but also in evaluating the effects of anti-inflammatory therapy. A volume-based analysis of parameters measured by FDG PET, so-called cardiac metabolic volume (CMV), has emerged as a new assessment tool. CMV is measured as the volume within the boundary determined by a reference tissue such as the liver and the blood pool uptake. However, there is a possibility that oral steroid therapy could lead to variations of the liver and the blood pool uptake. Here, we attempted to evaluate the steroid effects on the liver and the blood pool uptake. A total of 38 CS patients who underwent FDG PET/CT before and during steroid therapy were retrospectively enrolled. Volumes of interest (VOIs) were placed in the right lobe of the liver and descending aorta (DA). The maximum standardized uptake value (SUVmax), SUVmean, and SUVpeak of the liver and DA were compared between time points before and during steroid therapy. The SUVmax, SUVmean, and SUVpeak of the liver during steroid therapy significantly increased from the time point before the therapy (SUVmax 3.5 ± 0.4 vs. 3.8 ± 0.6, p = 0.014; SUVmean 2.7 ± 0.3 vs. 3.0 ± 0.5, p = 0.0065; SUVpeak 3.0 ± 0.4 vs. 3.4 ± 0.6, p = 0.006). However, the SUVmax, SUVmean, and SUVpeak in the DA did not significantly change (SUVmax 2.2 ± 0.3 vs. 2.2 ± 0.4, p = 0.46; SUVmean 1.9 ± 0.3 vs. 2.0 ± 0.4, p = 0.56; SUVpeak 2.0 ± 0.3 vs. 2.0 ± 0.3, p = 0.70). We measured FDG uptake in the liver and blood pool before and during steroid therapy. Steroid therapy increased the liver uptake but not the blood pool uptake. Our findings suggested that the DA uptake is a more suitable threshold than liver uptake to evaluate therapeutic effects using volume-based analysis of cardiac FDG PET.
登录
查看更多内容
DOI：
10.1007/s12350-015-0226-0
发表时间：
2016-04
期刊：
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
影响因子：
--
作者：
Manabe O;Yoshinaga K;Ohira H;Masuda A;Sato T;Tsujino I;Yamada A;Oyama-Manabe N;Hirata K;Nishimura M;Tamaki N
通讯作者：
Tamaki N
影响因子：
4
作者：
Keramida, Georgia;Hunter, James;Peters, Adrien Michael
通讯作者：
Peters, Adrien Michael
影响因子：
3.2
作者：
Ishiyama M;Soine LA;Vesselle HJ
通讯作者：
Vesselle HJ
影响因子：
9.8
作者：
Borra, Ronald;Lautamaki, Riikka;Nuutila, Pirjo
通讯作者：
Nuutila, Pirjo
影响因子：
4.3
作者：
Mostard, R. L. M.;Voo, S.;Drent, M.
通讯作者：
Drent, M.